When this combination was administered to an in vitro model of the tumor and interleukin (IL)-2 was added, an expansion in the number of tumor-specific CD8+ T cells and an improvement in the multifunctionality of pro-inflammatory cytokines were observed. The gene discussed is IL2; the disease is neoplasm.